Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Primary record20
fca_pdmr_buy
National Storage Mechanism | Additional information RNS Number : 8443B AOTI, Inc. 04 November 2026 4 November 2026 AOTI INC. (the "Company") Directors'/PDMR Shareholding - Employee Share Purchase Plan The Company was inf
Schrodinger, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026. A co
BIOADAPTIVES, INC. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Overview of the Membership Interest Purchase Agreement On October 29, 2026, BioAdaptives, Inc., a Delaware corporation (the “Company” or “Parent”), entered into a def
Ultragenyx Pharmaceutical Inc. filed 8-K
Item 2.01 Completion of Acquisition or Disposition of Assets. On October 30, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) completed the previously disclosed sale (the “PRV Sale”) of its Rare Pediatric Disease Pri
ACURA PHARMACEUTICALS, INC filed 8-K
Item 1.01 - Entry into a Material Definitive Agreement. On October 19 and October 30, 2026 we received loans of $41,607 and $100,000, respectively from Abuse Deterrent Pharma, LLC (“AD Pharma”). These loan combined with
Profound Medical Corp. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. On October 28, 2026, Profound Medical (U.S.) Inc. (“Profound U.S.”), a wholly owned subsidiary of Profound Medical Corp. (the “Company” or “Profound”), entered into
LIGAND PHARMACEUTICALS INC filed SCHEDULE 13D/A
(the "SEC") on July 3, 2025 (the "Original Schedule 13D"), as amended and supplemented by Amendment No. 1 filed with the SEC on November 10, 2025 ("Amendment No. 1" and, together with the Original Schedule 13D and this A
uniQure N.V. filed 8-K
Item 7.01 Regulation FD Disclosure. On November 2, 2026, uniQure N.V. (the “ Company ”) issued a press release announcing the U.S. Food and Drug Administration (“ FDA ”) has accepted for review the Biologics License Appl
NRX Pharmaceuticals, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On October 30, 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Company’s Abbreviated New Drug Applicat
INOVIO PHARMACEUTICALS, INC. filed 8-K
Item 7.01 Regulation FD Disclosure. As described in Item 8.01 below, on October 30, 2026, Inovio Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FD
Pelthos Therapeutics Inc. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. Merger Agreement On October 30, 2026, Pelthos Therapeutics Inc., a Nevada corporation (“ Pelthos ” or “ Public Company ”), Credit Card Merger Sub, Inc., a Delaware c
OMEROS CORP filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 28, 2026, the Compensation Committee (the “Committe
Rafael Holdings, Inc. filed 8-K
Item 2.02. Results of Operations and Financial Condition. On October 29, 2026, Rafael Holdings, Inc. (the “Company”) distributed over a wire service and posted an earnings release to the investors page of its website (ww
PALVELLA THERAPEUTICS, INC. filed 8-K
Item 8.01 Other Events. On October 28, 2026, Palvella Therapeutics, Inc. (the “ Company ”) issued a press release announcing that the U.S. Food and Drug Administration (“ FDA ”) has accepted for filing and granted Priori
ADIAL PHARMACEUTICALS, INC. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Chief Executive Officer The Board of Directors (t
Gossamer Bio, Inc. filed 8-K
Item 5.07 Submission of Matters to a Vote of Security Holders. The following is a brief description of the matter voted upon at the special meeting of stockholders of Gossamer Bio, Inc. (the “Company”) held on October 27
Longeveron Inc. filed 8-K
Item 8.01. Other Events. On October 26, 2026, Longeveron Inc. (the “Company”) a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions
Mirum Pharmaceuticals, Inc. filed 8-K
Item 8.01 Other Events. Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva On Oc
Senti Biosciences Holdings, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. CVR Agreement On October 21, 2026 (the “Closing Date”), in connection with the closing (the “Closing”) of the transactions contemplated by the Merger Agreement, Midco
Phathom Pharmaceuticals, Inc. filed 8-K
Item 8.01 Other Events. On October 26, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the U.S. Food and Drug Administration’s (“FDA’s”) establishment of a public docket (Docket No. FDA-2026-N-